Compare Albertsons Companies Inc (ACI) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs BioNano Genomics Inc — how do they compare? Albertsons Companies Inc trades at $12.01 (market cap $5.95B), while BioNano Genomics Inc trades at $1.2 (market cap $13.66M). The key difference: Albertsons Companies Inc is far larger — about 435.6× BioNano Genomics Inc's market cap, and Albertsons Companies Inc pays a 5.55% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ACI | BNGO | |
|---|---|---|
Market Cap | $5.95B | $13.66M |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $4.92 |
52-Week Low | $11.03 | $1.06 |
Enterprise Value | $21.35B | $16.26M |
Dividend Yield | 5.55% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons Companies (ACI) trades at $12.135, showing minimal daily movement with a 0.04% gain. The stock faces bearish technical signals despite recent insider buying by the CEO and CFO. Fundamentals reveal declining profitability with net income margin at just 0.08% and falling revenue growth, though valuation metrics like P/S of 0.08 appear attractive. Recent Q2 2026 earnings missed expectations, triggering a 22% selloff and multiple law firm investigations into potential securities violations.
ACI presents a high-risk opportunity with conflicting signals. While insider purchases and low valuation multiples suggest potential value, deteriorating margins, earnings misses, and legal scrutiny create significant headwinds. The stock's near-term trajectory depends on successful execution of the ACI Edge restructuring and digital initiatives to reverse profitability declines.
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
